Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Endokrynologia Polska
MENU
Shortcuts Submit an article Author Guidelines Polish Society of Endocrinology Reviewers 2022 Redeem voucher Abstracts, 5–7 May 2022, Gliwice

open access

Vol 69, No 3 (2018)
Original paper
Submitted: 2017-10-25
Accepted: 2017-12-28
Published online: 2018-04-12
View PDF Download PDF file
Get Citation

131-I MIBG therapy of malignant pheochromocytoma and paraganglioma tumours — a single-centre study

Agnieszka Kotecka-Blicharz1, Kornelia Hasse-Lazar1, Daria Handkiewicz-Junak1, Tomasz Gawlik1, Agnieszka Pawlaczek1, Małgorzata Oczko-Wojciechowska1, Barbara Michalik1, Sylwia Szpak-Ulczok1, Jolanta Krajewska1, Beata Jurecka-Lubieniecka1, Barbara Jarząb1
DOI: 10.5603/EP.a2018.0024
·
Pubmed: 29645065
·
Endokrynol Pol 2018;69(3):246-251.
Affiliations
  1. Department of Nuclear Medicine and Endocrine Oncology,, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Wybrzeża Armii Krajowej 15, 44-101 Gliwice, Poland

open access

Vol 69, No 3 (2018)
Original Paper
Submitted: 2017-10-25
Accepted: 2017-12-28
Published online: 2018-04-12

Abstract

Introduction: Pheochromocytomas and paragangliomas are rare tumors deriving from chromaffin cells of adrenal medulla or paraganglia. They are usually benign but 10-35% of them present malignant behavior. The aim of the study was to evaluate the efficacy and safety of 131-I MIBG therapy in malignant pheochromocytoma /paraganglioma patients (MPPGL). Material and methods: 18 patients (7 women and 11 men) were included in this study. Between 2002 and 2016 they underwent 131-I MIBG therapy because of MPPGL and their medical data were analyzed retrospectively. Clinical indications for the treatment included progressive disease or massive tissue involvement independently from disease progression. Tumor response for the first time was assessed 3 months after the last treatment according to Response Evaluation Criteria in Solid Tumors criteria and by 131-I MIBG scans. Results: The mean single dose used was 7.25 GBq (196 mCi) and mean cumulative dose 33.08 GBq ( 894 mCi). In 2 (11%) patients complete tumor response was achieved. In 1 (6%) patient partial response was obtained. In 13 (72%) patients stable disease was observed. In 2 (11%) patients progression was diagnosed three months after treatment discontinuation. In the whole studied group the progression free survival time was 85 months and overall 5-year survival was 87%. Conclusions: Radionuclide treatment with use of 131-I MIBG may be effective form of palliative treatment for patients with inoperative neoplasm spread, progressive disease or patients requiring alleviation of symptoms. < p > < /p >

Abstract

Introduction: Pheochromocytomas and paragangliomas are rare tumors deriving from chromaffin cells of adrenal medulla or paraganglia. They are usually benign but 10-35% of them present malignant behavior. The aim of the study was to evaluate the efficacy and safety of 131-I MIBG therapy in malignant pheochromocytoma /paraganglioma patients (MPPGL). Material and methods: 18 patients (7 women and 11 men) were included in this study. Between 2002 and 2016 they underwent 131-I MIBG therapy because of MPPGL and their medical data were analyzed retrospectively. Clinical indications for the treatment included progressive disease or massive tissue involvement independently from disease progression. Tumor response for the first time was assessed 3 months after the last treatment according to Response Evaluation Criteria in Solid Tumors criteria and by 131-I MIBG scans. Results: The mean single dose used was 7.25 GBq (196 mCi) and mean cumulative dose 33.08 GBq ( 894 mCi). In 2 (11%) patients complete tumor response was achieved. In 1 (6%) patient partial response was obtained. In 13 (72%) patients stable disease was observed. In 2 (11%) patients progression was diagnosed three months after treatment discontinuation. In the whole studied group the progression free survival time was 85 months and overall 5-year survival was 87%. Conclusions: Radionuclide treatment with use of 131-I MIBG may be effective form of palliative treatment for patients with inoperative neoplasm spread, progressive disease or patients requiring alleviation of symptoms. < p > < /p >

Full Text:

View PDF Download PDF file
Get Citation

Keywords

pheochromocytoma, paraganglioma, MIBG treatment

About this article
Title

131-I MIBG therapy of malignant pheochromocytoma and paraganglioma tumours — a single-centre study

Journal

Endokrynologia Polska

Issue

Vol 69, No 3 (2018)

Article type

Original paper

Pages

246-251

Published online

2018-04-12

Page views

3643

Article views/downloads

2590

DOI

10.5603/EP.a2018.0024

Pubmed

29645065

Bibliographic record

Endokrynol Pol 2018;69(3):246-251.

Keywords

pheochromocytoma
paraganglioma
MIBG treatment

Authors

Agnieszka Kotecka-Blicharz
Kornelia Hasse-Lazar
Daria Handkiewicz-Junak
Tomasz Gawlik
Agnieszka Pawlaczek
Małgorzata Oczko-Wojciechowska
Barbara Michalik
Sylwia Szpak-Ulczok
Jolanta Krajewska
Beata Jurecka-Lubieniecka
Barbara Jarząb

References (22)
  1. Lenders JWM, Duh QY, Eisenhofer G, et al. Endocrine Society. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014; 99(6): 1915–1942.
    CrossRefPubMed
  2. Harari A, Inabnet WB. Malignant pheochromocytoma: a review. Am J Surg. 2011; 201(5): 700–708.
    CrossRefPubMed
  3. Därr R, Lenders JWM, Hofbauer LC, et al. Pheochromocytoma - update on disease management. Ther Adv Endocrinol Metab. 2012; 3(1): 11–26.
    CrossRefPubMed
  4. Martucci VL, Pacak K. Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment. Curr Probl Cancer. 2014; 38(1): 7–41.
    CrossRefPubMed
  5. Lowery AJ, Walsh S, McDermott EW, et al. Molecular and therapeutic advances in the diagnosis and management of malignant pheochromocytomas and paragangliomas. Oncologist. 2013; 18(4): 391–407.
    CrossRefPubMed
  6. Gonias S, Goldsby R, Matthay KK, et al. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol. 2009; 27(25): 4162–4168.
    CrossRefPubMed
  7. Adjallé R, Plouin PF, Pacak K, et al. Treatment of malignant pheochromocytoma. Horm Metab Res. 2009; 41(9): 687–696.
    CrossRefPubMed
  8. Andersen KF, Altaf R, Krarup-Hansen A, et al. Malignant pheochromocytomas and paragangliomas - the importance of a multidisciplinary approach. Cancer Treat Rev. 2011; 37(2): 111–119.
    CrossRefPubMed
  9. Shapiro B, Sisson JC, Wieland DM, et al. Radiopharmaceutical treatment of malignant pheochromocytoma. J Nucl Med. 1984; 25(2): 197–206.
    PubMed
  10. Charbonnel B, Chatal JF, Brendel AJ, et al. [Treatment of malignant pheochromocytoma by 131-I-metaiodobenzylguanidine]. Ann Endocrinol (Paris). 1988; 49(4-5): 344–347.
    PubMed
  11. Krempf M, Lumbroso J, Mornex R, et al. Use of m-[131I]iodobenzylguanidine in the treatment of malignant pheochromocytoma. J Clin Endocrinol Metab. 1991; 72(2): 455–461.
    CrossRefPubMed
  12. Schlumberger M, Gicquel C, Lumbroso J, et al. Malignant pheochromocytoma: clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases. J Endocrinol Invest. 1992; 15(9): 631–642.
    CrossRefPubMed
  13. Sakahara H, Endo K, Saga T, et al. 131I-metaiodobenzylguanidine therapy for malignant pheochromocytoma. Annals of Nuclear Medicine. 1994; 8(2): 133–137.
    CrossRef
  14. Safford SD, Coleman RE, Gockerman JP, et al. Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery. 2003; 134(6): 956–62; discussion 962.
    CrossRefPubMed
  15. Gedik GK, Hoefnagel CA, Bais E, et al. 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2008; 35(4): 725–733.
    CrossRefPubMed
  16. Castellani MR, Seghezzi S, Chiesa C, et al. (131)I-MIBG treatment of pheochromocytoma: low versus intermediate activity regimens of therapy. Q J Nucl Med Mol Imaging. 2010; 54(1): 100–113.
    PubMed
  17. Shilkrut M, Bar-Deroma R, Bar-Sela G, et al. Low-dose iodine-131 metaiodobenzylguanidine therapy for patients with malignant pheochromocytoma and paraganglioma: single center experience. Am J Clin Oncol. 2010; 33(1): 79–82.
    CrossRefPubMed
  18. Loh KC, Fitzgerald PA, Matthay KK, et al. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest. 1997; 20(11): 648–658.
    PubMed
  19. Brans B, Monsieurs M, Laureys G, et al. Thyroidal uptake and radiation dose after repetitive I-131-MIBG treatments: influence of potassium iodide for thyroid blocking. Med Pediatr Oncol. 2002; 38(1): 41–46.
    PubMed
  20. Rutherford MA, Rankin AJ, Yates TM, et al. Management of metastatic phaeochromocytoma and paraganglioma: use of iodine-131-meta-iodobenzylguanidine therapy in a tertiary referral centre. QJM. 2015; 108(5): 361–368.
    CrossRefPubMed
  21. Samaan NA, Hickey RC, Shutts PE. Diagnosis, localization, and management of pheochromocytoma. Pitfalls and follow-up in 41 patients. Cancer. 1988; 62(11): 2451–2460.
    PubMed
  22. Wakabayashi H, Taki J, Inaki A, et al. Prognostic values of initial responses to low-dose (131)I-MIBG therapy in patients with malignant pheochromocytoma and paraganglioma. Ann Nucl Med. 2013; 27(9): 839–846.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl